文献速递妇科产科

老年晚期子宫内膜癌免疫治疗使用趋势:NCDB分析

Trends in immunotherapy utilization among older adults with advanced endometrial cancer: An NCDB analysis.
PubMed 文献 · Gynecol Oncol · 2026-10-16

该回顾性队列研究基于美国国家癌症数据库(NCDB),纳入2019至2023年确诊为III-IV期子宫内膜癌(EC)的≥65岁女性,评估免疫治疗(IO)使用的时间趋势及预测因素。结果显示IO使用率在所有年龄组均显著上升,但≥85岁患者使用率仍显著低于65-74岁组(aOR 0.41),非西班牙裔黑人和西班牙裔患者使用率也较低。

要点

  • 老年晚期EC患者IO使用率随时间显著增加,但≥85岁患者使用率仍低。
  • ≥85岁患者接受IO的调整比值比(aOR)为0.41(95%CI 0.32-0.52)。
  • 非西班牙裔黑人患者调整社会经济因素后仍少12%接受IO(aOR 0.88)。

核心结论

  • 尽管IO对晚期EC有临床获益,但老年患者中存在显著的年龄相关差异,≥85岁患者IO使用率显著更低。
  • 调整社会经济因素后,非西班牙裔黑人患者相比非西班牙裔白人患者接受IO的可能性仍低12%,提示存在其他障碍。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症数据库(NCDB),纳入2019-2023年确诊的III-IV期子宫内膜癌且年龄≥65岁的女性。
  • 共纳入38,931例晚期EC患者,其中21,272例(54.6%)年龄≥65岁。

主要发现

  • IO使用率在所有年龄组均随时间显著增加(P-trend <0.001)。
  • 2023年,1851例老年患者(40%)接受了IO,但≥85岁患者使用率仅为21.6%(55/255),显著低于其他年龄组(P < 0.001)。
  • 多变量分析显示,≥85岁患者相比65-74岁患者接受IO的aOR为0.41(95%CI 0.32-0.52;P < 0.001)。
  • 非西班牙裔黑人患者相比非西班牙裔白人患者接受IO的aOR为0.81(95%CI 0.73-0.90;P < 0.001),西班牙裔患者aOR为0.84(95%CI 0.71-0.99;P = 0.034)。
  • 调整社会经济因素后,非西班牙裔黑人患者接受IO的aOR为0.88(95%CI 0.77-0.99;P = 0.0034)。

临床怎么用

  • 临床医生应关注≥85岁晚期EC患者,评估其接受IO的获益与风险,避免因年龄因素导致治疗不足。
  • 应关注少数族裔患者(非西班牙裔黑人、西班牙裔)的IO可及性,识别并解决潜在的结构性障碍。

局限性

  • 本研究为回顾性分析,可能存在未测量的混杂因素。
  • NCDB数据可能未涵盖所有影响治疗选择的临床细节(如合并症、体能状态)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine temporal trends in immunotherapy (IO) adoption and identify factor-related disparities among older adults with advanced endometrial cancer (EC). METHODS: We conducted a retrospective cohort study using the National Cancer Database (NCDB), including women aged ≥65 years diagnosed with stage III-IV EC between 2019 and 2023. Temporal trends of IO use were assessed, and multivariable logistic regression identified predictors of IO utilization. RESULTS: Among 38,931 patients with advanced EC, 21,272 (54.6%) were aged ≥65 years. IO utilization increased significantly over time across all age groups (P-trend <0.001). By 2023, 1851 older adults (40%) received IO, but utilization remained substantially lower among patients aged ≥85 years (55/255, 21.6%; P < 0.001). On multivariable analysis, patients aged ≥85 years were significantly less likely to receive IO compared with those aged 65-74 years (adjusted odds ratio [aOR] 0.41; 95% CI, 0.32-0.52; P < 0.001). Non-Hispanic (NH)-Black (aOR 0.81; 95% CI, 0.73-0.90; P < 0.001) and Hispanic patients (aOR 0.84; 95% CI, 0.71-0.99; P = 0.034) were also less likely to receive IO compared with NH-White patients. After adjustment for socioeconomic factors, NH-Black was 12% less likely to receive IO (aOR 0.88; 95% CI, 0.77-0.99; P = 0.0034). CONCLUSION: Despite the proven clinical benefit of IO use for patients with advanced EC, substantial age-based disparities persist. A lower likelihood of IO receipt among NH-Black compared with NH-White patients was also observed even after adjustment for socioeconomic factors. These findings highlight the need for further investigation into clinical, socioeconomic, and structural barriers influencing treatment access in older and minoritized populations.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Assavapokee N, Gellman C, Blank SV, et al. Trends in immunotherapy utilization among older adults with advanced endometrial cancer: An NCDB analysis. Gynecol Oncol. 2026. PMID: 42887398. doi:10.1016/j.ygyno.2026.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。